M0235 Insurance Policy Changes

HCPCS M0235 is officially defined as "Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, first dose." HCPCS M0235 is referenced in 2 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS M0235 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.